{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T17:15:30Z","timestamp":1783185330311,"version":"3.54.6"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>The objective of this clinical review is to evaluate current literature and propose optimal dosing strategies for thrice-weekly postdialytic administration of select antimicrobial agents in individuals receiving chronic intermittent hemodialysis (iHD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>The optimization of outpatient parenteral antimicrobial therapy (OPAT) for patients receiving chronic iHD presents a prime opportunity for stewardship intervention. By utilizing the existing vascular hemodialysis access instead of inserting an additional peripheral catheter for antimicrobial administration, the risk for potential clinical complications (e.g. vein thrombosis, catheter-associated infections) can be minimized. In addition to vancomycin and aminoglycosides, literature evidence also supports the use of thrice-weekly cefazolin, ceftazidime, cefepime, ertapenem, and daptomycin given after dialysis sessions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Optimal dosing strategies of antimicrobials during transitions-of-care are imperative, especially in those receiving OPAT with iHD. While different dosing strategies may exist for each antimicrobial agent, other factors such as the modality of hemodialysis and site\/severity of infection should be considered when choosing the optimal dosing regimen.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxae259","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T11:48:40Z","timestamp":1727351320000},"page":"203-210","source":"Crossref","is-referenced-by-count":3,"title":["Important antimicrobial dosing considerations for transitions of care: Focus on thrice-weekly dosing in hemodialysis"],"prefix":"10.1093","volume":"82","author":[{"given":"Y Vivian","family":"Tsai","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Johns Hopkins Hospital , Baltimore, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Soto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Johns Hopkins Hospital , Baltimore, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett","family":"Crawford","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Johns Hopkins Hospital , Baltimore, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Dzintars","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Johns Hopkins Hospital , Baltimore, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"2025021005562570200_CIT0001","author":"Centers for Disease Control and Prevention","year":"2019"},{"issue":"3","key":"2025021005562570200_CIT0002","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.cmi.2019.09.016","article-title":"Post-discharge antimicrobial use among hospitalized patients across an integrated national healthcare network","volume":"26","author":"Feller","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"2025021005562570200_CIT0003","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2174\/1871526511313030008","article-title":"Infection and hemodialysis access: an updated review","volume":"13","author":"Gupta","year":"2013","journal-title":"Infect Discord Drug Targets"},{"issue":"suppl 1","key":"2025021005562570200_CIT0004","first-page":"S1","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for 2006 updates: hemodialysis adequacy, peritoneal dialysis adequacy and vascular access","volume":"48","author":"National Kidney Foundation","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2025021005562570200_CIT0005","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/cc1516","article-title":"Clinical review: use of vancomycin in haemodilaysis patients","volume":"6","author":"Launay-Vacher","year":"2002","journal-title":"Crit Care"},{"issue":"11","key":"2025021005562570200_CIT0006","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacist","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health-Syst Pharm"},{"issue":"2","key":"2025021005562570200_CIT0007","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cid\/cir322","article-title":"Weight-based loading of vancomycin in patients on hemodilaysis","volume":"53","author":"Brown","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025021005562570200_CIT0008","author":"Cefazolin","year":"1973"},{"issue":"3","key":"2025021005562570200_CIT0009","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1053\/ajkd.1998.v32.pm9740156","article-title":"Cefazolin as empiric therapy in hemodialysis-related infections: efficacy and blood concentrations","volume":"32","author":"Marx","year":"1988","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2025021005562570200_CIT0010","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0272-6386(01)80126-8","article-title":"Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers","volume":"37","author":"Sowinski","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"2025021005562570200_CIT0011","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/ajhp\/60.2.178","article-title":"Cefazolin dosing protocol for patients receiving long-term hemodialysis","volume":"60","author":"Ahern","year":"2003","journal-title":"Am J Health-Syst Pharm"},{"key":"2025021005562570200_CIT0012","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1093\/ndt\/14.8.2050","article-title":"Cefazolin serum concentrations with fixed intravenous dosing in patients on chronic hemodialysis treatment","volume":"14","author":"Kuypers","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"2025021005562570200_CIT0013","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1086\/510386","article-title":"Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia","volume":"44","author":"Stryjewski","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2025021005562570200_CIT0014","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/1471-2334-11-279","article-title":"Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia","volume":"11","author":"Schweizer","year":"2011","journal-title":"BMC Infect Dis"},{"key":"2025021005562570200_CIT0015","year":"1984"},{"key":"2025021005562570200_CIT0016","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-023-023-02167","article-title":"Ceftazidime-related neurotoxicity in a patient with renal impairment: a case report and literature review","author":"Vanneste","year":"2024","journal-title":"Infection"},{"issue":"5","key":"2025021005562570200_CIT0017","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1128\/AAC.25.5.638","article-title":"Pharmacokinetics of ceftazidime in normal and uremic subjects","volume":"25","author":"Leroy","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2025021005562570200_CIT0018","first-page":"142","article-title":"Effect of hemodialysis on ceftazidime pharmacokinetic","volume":"24","author":"Nikolaidis","year":"1985","journal-title":"Clin Nephrol"},{"issue":"12","key":"2025021005562570200_CIT0019","doi-asserted-by":"crossref","first-page":"5854","DOI":"10.1128\/AAC.00474-13","article-title":"Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis","volume":"57","author":"Loo","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2025021005562570200_CIT0020","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/jac\/dkz096","article-title":"Successful treatment of Pseudomonas aeruginosa infective endocarditis via haemodialysis outpatient parenteral antimicrobial therapy: a case report","volume":"74","author":"Maxwell-Scott","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025021005562570200_CIT0021","year":"2012"},{"issue":"4","key":"2025021005562570200_CIT0022","doi-asserted-by":"crossref","first-page":"ofx170","DOI":"10.1093\/ofid\/ofx170","article-title":"Characterizing cefepime neurotoxicity: a systematic review","volume":"4","author":"Appa","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2025021005562570200_CIT0023","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13054-017-1856-1","article-title":"Cefepime-induced neurotoxicity: a systematic review","volume":"21","author":"Payne","year":"2017","journal-title":"Crit Care"},{"issue":"10","key":"2025021005562570200_CIT0024","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1128\/AAC.01595-08","article-title":"High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function","volume":"54","author":"Lamoth","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2025021005562570200_CIT0025","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cmi.2017.01.005","article-title":"Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study","volume":"23","author":"Huwyler","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2025021005562570200_CIT0026","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s002280050721","article-title":"Multiple-dose pharmacokinetics of cefepime in long-term hemodialysis with high-flux membranes","volume":"56","author":"Schmaldienst","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"2025021005562570200_CIT0027","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1053\/j.ajkd.2012.01.012","article-title":"Cefepime for gram-negative bacteremia in long-term hemodialysis: a single-center experience","volume":"59","author":"Perez","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2025021005562570200_CIT0028","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40360-016-0048-y","article-title":"Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study","volume":"17","author":"Descombes","year":"2016","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"2025021005562570200_CIT0029","doi-asserted-by":"crossref","first-page":"312","DOI":"10.5414\/CN108071","article-title":"A practical thrice weekly ertaepenem dosage regimen for chronic hemodilaysis patients","volume":"80","author":"Geerlings","year":"2013","journal-title":"Clin Nephrol"},{"issue":"10","key":"2025021005562570200_CIT0030","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/ndt\/gfy166","article-title":"Pharmacokinetics and investigation of optimal dose ertapenem in intermittent hemodilysis patients","volume":"34","author":"Hsaiky","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"2025021005562570200_CIT0031","doi-asserted-by":"crossref","first-page":"e01427","DOI":"10.1128\/AAC.01427-19","article-title":"A thrice-weekly ertapenem regimen is practical for hemodilysis patients","volume":"63","author":"Ueng","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025021005562570200_CIT0032","author":"Meropenem","year":"1996"},{"issue":"11","key":"2025021005562570200_CIT0033","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3390\/antibiotics9110815","article-title":"The case for intermittent carbapenem dosing in stable haemodilysis patients","volume":"9","author":"Ho","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2025021005562570200_CIT0034","author":"Daptomycin","year":"2003"},{"key":"2025021005562570200_CIT0035","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatinine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2025021005562570200_CIT0036","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jac\/dkg337","article-title":"Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection mode","volume":"52","author":"Dandekar","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2025021005562570200_CIT0037","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.45.3.845-851.2001","article-title":"Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection","volume":"45","author":"Louie","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2025021005562570200_CIT0038","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/ndt\/gfp655","article-title":"Single-dose daptomycin pharmacokinetics in chronic haemodilysis patients","volume":"25","author":"Salama","year":"2010","journal-title":"Nephro Dial Transplant"},{"issue":"1","key":"2025021005562570200_CIT0039","first-page":"63","article-title":"Pharmacokinetics and safety of multiple doses of daptomycin 6 mg\/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis","volume":"75","author":"Benziger","year":"2011","journal-title":"Clin Nephrol"},{"key":"2025021005562570200_CIT0040","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"2025021005562570200_CIT0041","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/AAC.02000-12","article-title":"Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis","volume":"57","author":"Butterfield","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2025021005562570200_CIT0042","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3390\/antibiotics11060710","article-title":"A retrospective study on the effectiveness and safety of vancomycin versus daptomycin in hemodialysis patients","volume":"11","author":"Kato","year":"2022","journal-title":"Antibiotics (Basel)"},{"issue":"7","key":"2025021005562570200_CIT0043","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1592\/phco.31.7.665","article-title":"Safety of daptomycin in patients receiving hemodialysis","volume":"31","author":"Muller","year":"2011","journal-title":"Pharmacotherapy"},{"key":"2025021005562570200_CIT0044","author":"Clinical and Laboratory Standards Institute","year":"2023"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxae259\/59634009\/zxae259.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/4\/203\/59634009\/zxae259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/4\/203\/59634009\/zxae259.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T05:56:44Z","timestamp":1739167004000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/4\/203\/7775994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,9,26]]},"published-print":{"date-parts":[[2025,2,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxae259","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2,15]]},"published":{"date-parts":[[2024,9,26]]}}}